Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States.
No risks detected for ICY from our risk checks.
Flawless balance sheet with solid track record.
Share Price & News
How has Incyte's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ICY has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ICY underperformed the German Biotechs industry which returned -2.9% over the past year.
Return vs Market: ICY underperformed the German Market which returned 2.9% over the past year.
Price Volatility Vs. Market
How volatile is Incyte's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Incyte undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ICY (€70.94) is trading below our estimate of fair value (€119.88)
Significantly Below Fair Value: ICY is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ICY is poor value based on its PE Ratio (37.5x) compared to the Biotechs industry average (36.6x).
PE vs Market: ICY is poor value based on its PE Ratio (37.5x) compared to the German market (19.9x).
Price to Earnings Growth Ratio
PEG Ratio: ICY is poor value based on its PEG Ratio (1.5x)
Price to Book Ratio
PB vs Industry: ICY is overvalued based on its PB Ratio (6.5x) compared to the DE Biotechs industry average (3.2x).
How is Incyte forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ICY's forecast earnings growth (25.8% per year) is above the savings rate (-0.4%).
Earnings vs Market: ICY's earnings (25.8% per year) are forecast to grow faster than the German market (13.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ICY's revenue (14.8% per year) is forecast to grow faster than the German market (5.1% per year).
High Growth Revenue: ICY's revenue (14.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ICY's Return on Equity is forecast to be high in 3 years time (23%)
How has Incyte performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ICY has high quality earnings.
Growing Profit Margin: ICY's current net profit margins (20.7%) are higher than last year (5.8%).
Past Earnings Growth Analysis
Earnings Trend: ICY has become profitable over the past 5 years, growing earnings by 37.2% per year.
Accelerating Growth: ICY's earnings growth over the past year (308.2%) exceeds its 5-year average (37.2% per year).
Earnings vs Industry: ICY earnings growth over the past year (308.2%) exceeded the Biotechs industry -4.7%.
Return on Equity
High ROE: ICY's Return on Equity (17.2%) is considered low.
Return on Assets
Return on Capital Employed
How is Incyte's financial position?
Financial Position Analysis
Short Term Liabilities: ICY's short term assets ($2.5B) exceed its short term liabilities ($513.3M).
Long Term Liabilities: ICY's short term assets ($2.5B) exceed its long term liabilities ($315.0M).
Debt to Equity History and Analysis
Debt Level: ICY's debt to equity ratio (0.7%) is considered satisfactory.
Reducing Debt: ICY had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: ICY's debt is well covered by operating cash flow (3883.4%).
Interest Coverage: ICY's interest payments on its debt are well covered by EBIT (227x coverage).
Inventory Level: ICY has a low level of unsold assets or inventory.
Debt Coverage by Assets: ICY's debt is covered by short term assets (assets are 135.6x debt).
What is Incyte's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate ICY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ICY's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ICY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ICY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ICY's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Hervé Hoppenot (59yo)
Mr. Hervé Hoppenot has been the Chairman of the Board at Incyte Corporation since May 2015 and as its Chief Executive Officer and President since January 13, 2014. Mr. Hoppenot served as the Chief Commerci ...
CEO Compensation Analysis
Compensation vs Market: Hervé's total compensation ($USD9.31M) is above average for companies of similar size in the German market ($USD4.64M).
Compensation vs Earnings: Hervé's compensation has been consistent with company performance over the past year.
|Executive VP & General Counsel||1.8yrs||US$3.62m||0.0018% $264.6k|
|Executive VP & Head of Discovery Chemistry||5.3yrs||US$6.54m||0.014% $2.2m|
|Executive VP & Chief Medical Officer||4.9yrs||US$6.61m||0.0012% $173.4k|
|Executive VP & CFO||1yrs||no data||0.00097% $145.0k|
|Executive VP & Head of Global Technical Operations||4.1yrs||no data||0.016% $2.3m|
|Executive VP & Chief Scientific Officer||1.2yrs||no data||0.00055% $82.2k|
|Divisional Vice President of Investor Relations & Corporate Social Responsibility||5.9yrs||no data||no data|
|Vice President of Investor Relations & Corporate Communications||0yrs||no data||no data|
|Executive VP of Global Strategy & Corporate Development||3.8yrs||no data||0.0023% $348.3k|
Experienced Management: ICY's management team is considered experienced (4.1 years average tenure).
|Independent Director||19.1yrs||US$522.37k||0.11% $16.6m|
|Independent Director||5.1yrs||US$485.37k||0.0027% $409.6k|
|Vice Chairman & Lead Independent Director||6.1yrs||US$503.37k||0.26% $38.6m|
|Independent Director||3.1yrs||US$477.37k||0.00071% $106.1k|
|Independent Director||18.3yrs||US$477.37k||0.12% $18.6m|
|Independent Director||9.8yrs||US$492.37k||0.0051% $759.4k|
|Director||0.2yrs||no data||no data|
|Independent Director||5.1yrs||US$497.37k||0.00043% $64.3k|
Experienced Board: ICY's board of directors are considered experienced (5.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Incyte Corporation's company bio, employee growth, exchange listings and data sources
- Name: Incyte Corporation
- Ticker: ICY
- Exchange: DB
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$16.440b
- Listing Market Cap: US$14.949b
- Shares outstanding: 216.78m
- Website: https://www.incyte.com
Number of Employees
- Incyte Corporation
- 1801 Augustine Cut-Off
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|INCY||NasdaqGS (Nasdaq Global Select)||Yes||Common Shares||US||USD||Nov 1993|
|ICY||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Nov 1993|
|INCY||WBAG (Wiener Boerse AG)||Yes||Common Shares||AT||EUR||Nov 1993|
|0J9P||LSE (London Stock Exchange)||Yes||Common Shares||GB||USD||Nov 1993|
|ICY||ETLX (Eurotlx)||Yes||Common Shares||IT||EUR||Nov 1993|
|INCY *||BMV (Bolsa Mexicana de Valores)||Yes||Common Shares||MX||MXN||Nov 1993|
|I1NC34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 2 REPR 1 COM||BR||BRL||Jan 2020|
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host diseases (GVHD); and Phase III trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat steroid-naïve acute and chronic GVHD, as well as Phase III clinical trial for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase III clinical trial for treating cholangiocarcinoma, and Phase II for treating bladder cancer, 8p11 myeloproliferative syndrome, and tumor agnostic. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/28 20:32|
|End of Day Share Price||2020/02/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.